A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine (Infanrix-HexaTM) with a 13-valent pneumococcal conjugate vaccine and incorporating a randomisation study of a single dose of 3 different meningococcal group C conjugate vaccines at 3 months of age

Trial Profile

A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine (Infanrix-HexaTM) with a 13-valent pneumococcal conjugate vaccine and incorporating a randomisation study of a single dose of 3 different meningococcal group C conjugate vaccines at 3 months of age

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Acronyms Infanrix-Hexa
  • Most Recent Events

    • 04 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
    • 15 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top